Skip to main content
. Author manuscript; available in PMC: 2017 Dec 18.
Published in final edited form as: Cancer Chemother Pharmacol. 2017 Aug 2;80(3):631–643. doi: 10.1007/s00280-017-3409-3

Figure 2.

Figure 2

(A) Plasma (day -2 (X) and day 1 (■)) and ascites (day 1 (●)) concentrations of veliparib in the patient with ascites. (B) Day 1 plasma concentrations of veliparib in the patient with ascites (■) compared to concentrations in five patients without ascites treated at the veliparib dose level. (C) PARP activity in PBMCs (□) and ascites cells (■) in a patient treated with 10 mg veliparib BID and 750 mg/m2 gemcitabine. Time 0 is start of gemcitabine infusion.